Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 11:15:53 Source:businessViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Supreme Court: CFPB funding doesn't violate Constitution
Next:Judge dismisses felony convictions of 5 retired military officers in US Navy bribery case
You may also like
- Germany and Real Madrid great Toni Kroos to retire after Euro 2024
- When Chinese martial arts, Western contemporary dance converge
- Delicacies from home and abroad gather at CICPE
- China may overtake Japan in patent filings at EPO
- Tianjin's century
- Joint exhibition of tri
- An extinct, deeply divergent tiger lineage identified in northeastern China: study
- Art education on display
- Hometown of Laura Ingalls Wilder set for a growth spurt